泰来肽治疗慢性乙肝疗效观察  

Application of Tailaitai in the Treatment of Chronic Hepatitis B

作　　者：叶非[1] 

机构地区：[1]杭州市第六人民医院,310014

出　　处：《医学研究通讯》2005年第12期36-37,共2页Bulletin of Medical Research

摘　　要：观察泰来肽对慢性乙肝的疗效和安全性。167例患者分三组观察,治疗组56例在一般保肝治疗基础上泰来肽4ML 肌注连用3个月;联合组泰来肽4ml 每日肌内注射,连用3个月加上苦参素100ml 静滴每日一次,连用3个月;对照组56例仅用常规保肝药物治疗,疗程三个月。结果 ALT 复常率治疗后、停药后3个月治疗组和联合治疗组均较对照组高,但差异无显著性(P>0.05)。治疗组和联合组 HBVM 转阴率与对照组相比差异有显著性(P<0.01),但治疗组与联合组相比差异无显著性(P>0.5)。泰来肽具有良好的疗效和安全性。To observe the effect of tailaitai in the treatment of chronic hepatitis B and its safety. A total of 167 cases with CHB were divided into three groups. Group A （tailaitai treated group） were given tailaitai 4ml intramuscular injection qd for three months, group B were given tailaitai 4ml intramuscular injection qd combined with kushensu intravenous injection 100ml qd for three months, group C were given symptomatic treatment for three months. The results showed in group A and group B the recovery rate of ALT after therapy and three months after quit the drug were higher than group C, but didn＇t show a significant difference as compared with it （P 〉 0.05）. The negative conversion rote of HBVM in group A and group B were significantly higher than group C （P 〈 0.01）, but group A＇s negative conversion rate didn＇t show a significant difference as compared with group B （P 〉 0.5）. Tailaital has good curative effect and safeness in the treatment of chronic hepatitis B.

关 键 词：泰来肽 乙型肝炎 治疗 苦参素 药物治疗 

分 类 号：R512.62[医药卫生—内科学] R22[医药卫生—临床医学]